











Is there a common cause for paediatric Cushing’s disease?
Katarzyna Pasternak-Pietrzak 1, Fabio R. Faucz 2, Constantine A. Stratakis2, Elżbieta Moszczyńska1, 
Marcin Roszkowski3, Wiesława Grajkowska4, Maciej Pronicki4, Mieczysław Szalecki1, 5
1Department of Endocrinology and Diabetology, The Children’s Memorial Health Institute (CMHI), Warsaw, Poland 
2Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
National Institutes of Health, Bethesda, Maryland, United States 
3Department of Neurosurgery, The Children’s Memorial Health Institute (CMHI), Warsaw, Poland
4Pathology Department, The Children’s Memorial Health Institute, Warsaw, Poland
5Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Abstract 
Introduction: According to recent literature, somatic mutations in the ubiquitin-specific protease 8 (USP8) gene are the most common 
changes in patients with Cushing’s disease (CD). Data on the frequency of these mutations in the paediatric population are limited. The 
aim of the presented study was to determine the frequency of the USP8 gene mutations in a group of paediatric patients with CD treated 
at the Children’s Memorial Health Institute (CMHI). 
Material and methods: Eighteen patients (nine females) with CD were treated at CMHI, Warsaw, Poland between 1993 and 2019. All 
patients underwent transsphenoidal surgery (TSS) as a primary treatment for CD. The average age of all patients at TSS was 13.10 years 
(5.42–17.25). DNA was extracted from formalin-fixed paraffin-embedded resected tumour tissue. Sanger sequencing was performed on 
DNA sequence corresponding to the exon 14 of USP8 gene. 
Results: The mean age at diagnosis of CD was 13.08 years, and the average duration of symptoms before diagnosis was 2.96 years. All 
patients were operated at CMHI by the same neurosurgeon. Fifteen out of 18 patients (83.33%) had initial biochemical remission after 
a single TSS procedure (post-operative serum cortisol < 1.8 μg/dL). The result of genetic testing was negative for all samples at the hotspot 
area of the USP8 gene. 
Conclusion: The current retrospective study demonstrates that mutations in the USP8 gene may not be as common a cause of paediatric 
Cushing’s disease, as previously reported. (Endokrynol Pol 2021; 72 (2): 104–107)
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Introduction
Paediatric Cushing’s disease (CD) is characterised by 
growth retardation with concomitant weight gain 
as well as other classic clinical features of CD (skin 
changes, psychiatric disorders, decreased bone mineral 
density, weakness, and others) caused by excessive se-
cretion of adrenocorticotropic hormone (ACTH) [1–3]. 
The first-line treatment is transsphenoidal surgical 
resection (TSS) of the pituitary adenoma [4–6]. 
According to recent literature, somatic variants in 
the USP8 gene encoding ubiquitin-specific protease 
8 (USP8), clustered into a hotspot region overlapping 
with the 14-3-3 binding motif, are the most important 
in CD pathogenesis. The frequency of these variants 
is estimated to be 31–63%, but the performed studies 
have mainly concerned adult patients [7–11]. The 
effect of this mutation is increased deubiquitina-
tion of epidermal growth factor and thus increased 
induction of proopiomelanocortin transcription and 
secretion of ACTH [7]. Literature data on the clinical 
significance of the presence of mutations in the USP8 
gene in children are limited. There has only been one 
study on children, made by Faucz et al. on a group of 
42 children aged 6.1–18.7 years with CD, indicating 
a frequency of somatic variants in the USP8 gene of 
around 30% [8]. At the same time, published results 
indicate a different course of disease in children than 
in adults, with an increased risk of recurrence in the 
group of patients with a variant in the USP8 hotspot 
[8]. The need for additional research is emphasised 
to verify the observed correlation. Hayashi et al. also 
showed that tumours with USP8 variants have more 
type 5 somatostatin receptors that can be a therapeutic 
target with specific somatostatin analogues such as 
pasireotide [11].
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(BigDye Terminator 3.1 Cycle Sequencing Kit — 4337456, Applied 
Biosystems, Foster City, California) using a 3500xL Genetic Analyzer 
(Applied Biosystems) was performed. Sequences were analysed us-
ing Geneious Prime software v.2019.0.4 (Biomatters, San Diego, CA).
Results
Patient characteristics
In our group of 18 patients there was no sex predomi-
nance (Tab. 1). The mean age at diagnosis of CD was 
13.08 years, and the average duration of symptoms 
before diagnosis was 2.96 years. The mean midnight 
serum cortisol and 24-hour urinary free cortisol (UFC) 
levels were 23.17 μg/dL and 692.43 μg/24 hours, re-
spectively. In every patient 24-h urine free cortisol was 
increased [16]. Two of the 18 patients (11.12%) presented 
with evidence of cavernous sinus invasion (in one 
patient cavernous sinus invasion was detected after 
TSS2). In one patient (5.56%) the tumour penetrated 
the cavernous sinus and did not infiltrate its walls but 
dislocated the sinus. 
Transsphenoidal pituitary surgery 
All patients were operated at CMHI by the same neuro-
surgeon. Fifteen out of 18 patients (83.33%) had initial 
biochemical remission after a single TSS procedure 
(post-operative serum cortisol < 1.8 μg/dL [17]). One of 
three patients who did not have biochemical remission 
after TSS1 had successful hypophysectomy one year 
after TSS1. The overall rate of remission following TSS 
was 88.9%. In one patient biochemical remission was 
achieved after radiotherapy.
Pituitary histology
Histopathological examination confirmed corticotroph 
adenoma in 16/18 (88.9%) patients. Histopathological 
examinations of two patients revealed focal corticotroph 
hyperplasia and normal pituitary gland, respectively. 
Material and methods
Eighteen patients (nine females) with diagnosed CD were treated at 
the Children’s Memorial Health Institute (CMHI), Warsaw, Poland 
between 1993 and 2019. All patients underwent TSS as a primary 
treatment for CD (all patients were operated by the same neuro-
surgeon at CMHI). The average age of all patients at TSS was 13.10 
years (5.42–17.25). The Institutional Bioethical Commission (10/
KBE/2019) approved this study. Written informed consent from 
the parents and assent from the minor patients were obtained.
After excluding 12 patients (from 30 patients with CD) because of 
lack of patient’s consent for genetic testing and/or lack of inability to 
obtain patient’s consent or lack of material because surgery was out-
side CMHI, our study was performed on 22 tumour samples from 18 
patients. Two samples from TSS2 were analysed. An additional two 
samples were from TSS1 of the same patient. Genetic testing was 
performed at the National Institutes of Health, Bethesda, MD. The 
tumour samples were anonymised so that no personal data were 
revealed to the centre carrying out the tests. The genetic material 
was resected tumour tissue secured in the form of paraffin blocks.
The obtained anthropometric parameters were presented as 
standard deviations (SDS) for BMI using the LMS method [12, 13]. 
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The L, M, and S values were taken from the tables of the reference 
system for a given age and sex [14, 15].
Cortisol levels at night were defined as the mean values of two 
measurements, respectively: cortisol level at 00.00 H and 00.30 H. 
High 24-h urine free cortisol was defined as free urine cortisol more 
than 80 μg/m2 [16]. The disease onset was defined as the moment 
when the first symptom of the disease occurred.
DNA was extracted from microdissected tumour tissues with 
the PinpointTM Slide Isolation System (Zymo, Irvine, CA). DNA 
was extracted after confirming that the selected cut of the tissue 
originated exclusively from the corticotroph adenoma, to exclude 
the possibility of mixing the tumour DNA sample with DNA from 
normal cells. 
Somatic DNA encompassing the exon 14 hotspot region of the 
USP8 gene (amino acids 718 to 721) was amplified by end-point 
PCR (GoTaq Green Master Mix — M7123, Promega, Durham, NC) 
using the following primers: forward, 5’-CTTGACCCAATCACT-
GGAAC-3’ and reverse, 5’- TTACTGTTGGCTTCCTCTTCTC-3’. 
PCR product was purified (ExoSAP-IT™ Express — 75001.1.ML, 
Thermofisher — Waltham, MA) and direct bidirectional sequencing 
Table 1. Data of analysed group of patients
Average Min Max
Age at diagnosis [years] 13.08 5.5 17.3
Time from first symptom to diagnosis [years] 2.92 0.8 9.00
Female sex n (%) 50.0
BMI [kg/m2] 24.27 19.53 31.50
BMI SDS 1.43 –0.30 2.48
Midnight plasma cortisol [μg/dL] 23.17 9.1 52.14
24-hour UFC [μg/24 h] 692.43 199.3 2263.2
Max. morning serum ACTH 131.23 49 536
Invasion to cavernous sinus, n (%) 2/18 (11.12%)
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Follow-up
During a mean of 3.37 years. (0.17–8.33) of follow-up 
at CMHI, 15 patients (83.3%) were in remission, and 
one patient (5.56%) had recurrence of the disease. One 
patient died one month after TSS2 as a result of post-
operative complications, and one patient had a persis-
tent disease after TSS1 and TSS2 and was undergoing 
radiotherapy at latest follow-up.
Frequency of USP8 gene mutations
None of the samples showed any pathogenic variants 
at the known USP8 hotspot region. One rare synony-
mous variant (c.2154C>T / p.Ser718= / rs1261832527 / 
/ 0.0007%) was identified in the hotspot area. Sur-
rounding the USP8 hotspot area a new missense 
variant (predict as benign by PolyPhen in silico tool 
— http://genetics.bwh.harvard.edu/pph2/) was also 
identified: the variant p.Thr723Ile is formed by a transi-
tion from a C to a T at position 2168 (c.2168C>T).
Discussion
Somatic variants in the ubiquitin 8 specific protease 
gene have recently been identified as the most com-
mon changes in patients with CD. Including the 
studies of Reincke et al. (17 patients aged 33–56 yrs) 
[9], Perez-Rivas et al. (145 patients aged 7–76 yrs) 
[7], Ma et al. (120 patients aged 26–46 yrs) [10], and 
Albani et al. (34 patients aged 39–61 yrs) [18], the total 
frequency of USP8 hotspot variants varies between 
35 and 63%. Until now the paediatric population has 
not been extensively assessed, and its real frequency 
remains uncertain. In a recent study by Perez-Rivas 
et al. the frequency of USP8 variants was lower in 
children than in adults (17% vs. 36%) [7]. In the big-
gest and the only paediatric study, the frequency of 
genetic changes in USP8 gene was 31% [8]. In the 
present study, we did not find any pathogenic vari-
ants within the known USP8 hotspot region, com-
prising the amino acids 718 to 721. It is possible that 
a different population in the presented study could 
have influenced the results.
From the two variants identified in exon 14 in the 
presented study one was synonymous and within the 
hotspot region (p.Ser718=) and another was located 
nearby (p.Thr723Ile). Both were somatic. Because the 
first one is synonymous it is probably not related to 
the phenotype; however, without functional analysis, 
a creation of a splice site, for example, cannot be ruled 
out. For the p.Thr723Ile, even though an in silico tool 
predicted it as benign, the variant is very close to the 
hotspot, and the amino acid is highly conserved. How-
ever, so far, all disease-causing variants are located in 
the hotspot region, and position 723 does not seem to 
affect the 14-3-3 binding motif; so probably this vari-
ant also does not contribute to the formation of the 
corticotropinoma. Despite the low possibility of those 
two variants cause Cushing’s disease, in the absence 
of functional studies is difficult to know if they are 
somehow responsible for the development of Cush-
ing’s disease in those patients. Additional functional 
tests should be performed in those two variants to rule 
them out as Cushing’s disease drivers. Unfortunately, 
there were no conditions to perform such tests in the 
present work.
The identification of a molecular pathogenesis of 
CD is important because identified mutations create the 
opportunity to use new treatment targets. The results 
of our study imply the need for further research into 
other possible causes of CD in children. Among the 
possible somatic changes found in patients with CD 
are mutations in the following genes: GNAS1, TP53, 
NR3C1 (Nuclear Receptor Subfamily 3 Group C Mem-
ber 1), NR0B1 (Nuclear receptor subfamily 0 group B 
member 1), Brg1 (brahma-related gene 1), and HDAC2 
(Histone Deacetylase 2) [19–22]. Moreover, transcrip-
tion factors associated with progenitor proliferation 
and differentiation (such as TPIT, PROP1, LHX3, LHX4, 
or HESX1) as well as somatic mutations in genes that 
cause syndromes associated with pituitary adenomas 
(MEN1, PRKAR1A, AIP) can be associated with mo-
lecular changes resulting in CD [23, 24]. However, the 
frequency of mutations in the above-mentioned genes 
is very low, and only a few literature reports add them 
to the range of potential factors in CD. In a study by 
Williamson et al. a variant in the GNAS was identified 
only in 2/32 ACTH-secreting adenomas [19]. Riminucci 
et al. reported a case report of an 11-year-old girl with 
CD with activating mutation in the GNAS gene. The 
girl did not achieve remission after TSS but only after 
radiotherapy [25]. 
Among the germline variants in patients with CD 
there are some genetic changes in genes such as MEN1, 
CDKN1B (MEN4), AIP, DICER1, and CABLES1; how-
ever, they are not responsible for a significant number of 
CD cases. Stratakis et al. studied a group of 74 children 
with CD, and germline changes in MEN1 were detected 
in only two patients with positive family history with 
MEN1 [26]. The disease in these patients was recurrent 
or difficult to treat [26].
According to the literature, the USP8 mutational 
status could predict remission and/or recurrence in pa-
tients with CD [18]. Our objective was also to correlate 
the presence of somatic USP8 mutations with the rate 
of recurrence after successful TSS. Unfortunately, the 
negative results obtained prevent us from making such 
an analysis and from comparing between groups with 
and without a variant in the USP8 gene. 
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The presented retrospective study demonstrates that 
variants in the USP8 gene may not be a common cause 
of paediatric Cushing’s disease in the cohort popula-
tion. The knowledge about molecular background 
of corticotroph adenomas is still not entirely known. 
Future genetic research is essential to determine the 
pathology of Cushing’s disease.
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